1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd.

TTSE:4512
302.00
JPY
+1.00
(+0.33%)
12.18BMarket Cap
Nov 06Next Earn
Wakamoto Pharmaceutical Co., Ltd.
TSE:4512
(Tokyo Stock Exchange)

Recent

price

302.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
279.57
270.38
285.27
296.92
308.87
322.28
311.95
314.02
309.5
314.57
256.28
241.54
249.53
222.97
224.44
285.45
- -
Revenue per Share
-12.3
-3.52
5.27
24.3
2.4
0.59
2.73
3.63
-5.22
-47.73
-17.34
6.87
3.98
3.14
1.86
6.55
- -
Basic EPS, GAAP
-3.79
-3.95
18.77
25.67
-1.87
3.22
21.59
2.18
-20.48
-10.44
-9.19
-0.04
12.12
-20.23
-31.38
-32.89
- -
Free Cash Flow per Basic Share
2.51
0.07
0.03
0.03
2.98
2.99
2.99
2.99
2.98
0.02
0.01
0.01
0.01
2.99
2.98
3
- -
Dividend per Share
349.49
347.39
363.37
397.37
406.54
401.79
400.23
406.45
396.47
344.21
328.04
330.79
343.06
346.51
334.53
346.01
- -
Book Value per Share
346.42
335.68
350.39
384.45
393.95
388.66
388.29
393.1
382.87
330.24
322.24
325.14
337.24
336.22
326.53
339.05
- -
Tangible Book Value per Share
35
35
35
35
35
35
35
35
35
35
35
35
35
35
35
35
35
Basic Weighted Avg Shares
9,672
9,409
9,924
10,324
10,733
11,194
10,833
10,901
10,742
10,918
8,895
8,383
8,660
7,738
7,789
9,907
- -
Sales/Revenue/Turnover
-7.81
-5.37
0.21
1.55
1.89
0.74
0.81
-0.67
-3.64
-9.13
-8.49
-0.16
1.63
-2.53
-5.88
2.58
- -
Operating Margin (%)
1,205
1,008
787
707
767
746
659
527
468
465
484
470
446
412
430
443
- -
Depreciation Expense
-426
-122
183
845
83
21
95
126
-181
-1,657
-602
239
138
109
64
227
- -
Net Income, GAAP
- -
- -
59.13
37.83
64.02
83.73
44.26
27.68
- -
- -
- -
16.26
34.65
31.41
- -
11.38
- -
Effective Tax Rate (%)
-4.4
-1.3
1.85
8.18
0.78
0.18
0.87
1.16
-1.69
-15.17
-6.77
2.85
1.6
1.41
0.83
2.29
- -
Profit Margin (%)
5,920
6,372
7,094
6,368
7,019
6,988
7,322
7,165
6,916
6,213
5,925
6,599
7,114
7,162
6,873
6,891
- -
Working Capital
1,230
1,334
1,102
216
688
372
209
45
2
4
3
2
1
- -
- -
262
- -
LT Debt
12,165
12,102
12,639
13,813
14,124
13,955
13,897
14,107
13,761
11,947
11,386
11,481
11,907
12,026
11,610
12,009
- -
Total Equity
- -
- -
0.06
0.65
0.46
0.09
0.33
-0.37
- -
- -
- -
-0.1
0.77
-1.1
- -
1.85
- -
Return on Invested Capital (%)
- -
- -
1.36
5.75
0.57
0.14
0.66
0.89
- -
- -
- -
2.06
1.17
0.9
- -
1.9
- -
Return on Capital (%)
-3.43
-1.01
1.48
6.39
0.6
0.15
0.68
0.9
-1.3
-12.89
-5.16
2.09
1.18
0.91
0.55
1.92
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
138
- -
LT Borrowings
- -
262
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
9,926
12,182
9,336

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,672
- -
Cash, Cash Equivalents & STI
- -
2,006
- -
Accounts Receivable, Net
- -
3,484
- -
Inventories
- -
3,922
- -
Total Current Liabilities
- -
2,781
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
138
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.37%
1.1%
3.43%
Free Cash Flow
-3,551.17%
-6,978.96%
4.81%
Net Income, GAAP
90.99%
1.78%
252.6%
Sales/Revenue/Turnover
-0.62%
2.95%
27.18%
Total Cash Common Dividend
2,142.4%
4,308%
0.68%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
7,789
2026
- -
- -
- -
- -
9,907
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.86
2026
- -
- -
- -
- -
6.55
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.98
2026
- -
- -
- -
- -
3
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Wakamoto Pharmaceutical Co., Ltd. (Ticker: 4512.T) develops, manufactures, and markets pharmaceutical and quasi-drug products primarily focused on gastrointestinal health and probiotics in Japan. The company offers a range of proprietary probiotic formulations, including its flagship Wakamoto brand tablets and capsules containing multiple beneficial bacteria strains such as Clostridium butyricum and Bacillus subtilis for digestive support; lactic acid bacteria drinks and supplements; antibiotics like antibacterial agents for intestinal infections; and over-the-counter remedies for stomach ailments, constipation, and dysbiosis. It also provides contract manufacturing services for third-party pharmaceutical products and engages in research on microbial therapeutics. Founded in 1916 and headquartered in Tokyo, Japan, Wakamoto Pharmaceutical operates predominantly in the domestic market, serving consumers, pharmacies, hospitals, and retailers through a network of distributors. The company belongs to the pharmaceuticals industry, with business segments in ethical drugs, OTC medicines, and health foods targeting patients with gut-related disorders and general wellness seekers. It maintains subsidiaries for sales and production but has no major parent company. In recent developments, Wakamoto Pharmaceutical expanded its probiotic portfolio with new formulations incorporating postbiotics in 2024, enhancing product stability for broader applications in functional foods. The company formed a strategic alliance with a leading Japanese dairy producer in early 2025 to co-develop fermented milk products featuring its proprietary strains, aiming to enter the functional beverage market. Additionally, it completed a minor acquisition of a small biotech firm specializing in microbiome research in late 2024, bolstering its R&D capabilities amid growing demand for gut health solutions.